Brief: Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025
25/04/2025 21:54
April 25 (Reuters) - Inhibikase Therapeutics Inc IKT.O: Q32 BIO INC - MARK IWICKI RESIGNS FROM Q32 BIO BOARD EFFECTIVE DEC 31, 2025 Q32 BIO INC - IWICKI RESIGNS TO FOCUS ON CEO ROLE AT INHIBIKASE THERAPEUTICS Source text: [ID:n0001193125-25-096703] Further company coverage: IKT.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary